COVID
Conditions
Brief summary
The objectives of this study are to characterise immune responses in people with CoV-SARS-2 infection and use this knowledge to advance vaccine design, treatment options, and diagnostic reagents. Eligible participants will include people diagnosed with SARS-CoV-2 infection, and may include recently returned travellers and non-travellers in the community presenting to tertiary hospital healthcare facilities. Recruitment will be opportunistic, and sampling intensity may vary depending on the phase of the outbreak. Participants can be enrolled at any timepoint (up to 6 months) following diagnosis of SARS-CoV-2 infection (COVID-19). Blood samples and clinical data will be collected.
Interventions
OTHERBiological sample and clinical data collection
Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
Sponsors
Kirby Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Main cohort 1. Diagnosed with CoV-SARS-2 infection 2. 16 years of age or older 3. Have provided informed consent Paediatric cohort <!-- --> 1. Diagnosed with CoV-SARS-2 infection 2. Less than 16 years of age 3. Informed consent provided by parent or caregiver
Exclusion criteria
Main cohort <!-- --> 1. 15 years of age or younger 2. Inability or unwillingness to provide informed consent or abide by the requirements of the study Paediatric cohort <!-- --> 1. 16 years of age or older 2. Inability or unwillingness of parent or caregiver to provide informed consent or abide by the requirements of the study -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Coronavirus sequencing | 4 months post COVID-19 diagnosis. | The viruses will be sequenced to to help understand epitope specificity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Coronavirus culturing | 4 months post COVID-19 diagnosis. | The viruses will then be either cultured to study the immune response against them in culture. |
Countries
Australia
Contacts
Primary ContactRowena Bull
Backup ContactMarianne Martinello
Outcome results
None listed